Search Results for: vedolizumab

February 26, 2020February 26, 2020

New Entyvio Formulation – Given as Injection at Home – Leads to Crohn’s Remission After One Year, Takeda Announces

News

Maintenance therapy with Entyvio‘s new formulation as a subcutaneous, or under-the-skin injection (SC) led more people with moderate-to-severe, active Crohn’s disease (CD) to achieve clinical remission after one year, compared ... Read more

February 3, 2020February 3, 2020

Study Identifies Risk Factors for the Poor Sleep Experienced by Two-thirds of IBD Patients

News

Researchers have identified risk factors — greater disability, lower quality of life, and non-intestinal symptoms — for the poor sleep experienced by two-thirds of patients with inflammatory bowel disease (IBD). ... Read more

January 22, 2020January 22, 2020

Phase 2 Trial of Oral Treatment for Ulcerative Colitis Expanding to US, Abivax Says

News

The U.S. Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for ABX464, Abivax’s treatment candidate for ulcerative colitis (UC), allowing the company to expand its Phase ... Read more

December 11, 2019December 11, 2019

Engitix, Morphic Partner to Identify New Ways of Treating Intestinal Fibrosis in IBD Patients

News

Engitix and Morphic Therapeutic announced the start of a research partnership into extracellular matrix targets for treating inflammatory bowel disease (IBD) with intestinal fibrosis, known as fibrostenotic IBD. The extracellular matrix ... Read more

December 2, 2019December 2, 2019

Abivax’s Phase 2b Trial Testing ABX464 for Ulcerative Colitis Cleared to Add French Sites

News

France’s National Agency for the Safety of Medicine and Health Products (ANSM) has cleared the inclusion of French study sites for Abivax‘s new Phase 2b clinical trial, intended to evaluate ... Read more

October 25, 2019October 25, 2019

One-year Data Support Efficacy and Safety of Abivax’s ABX464 for Ulcerative Colitis

News

Abivax has announced data from a long-term trial that continues to support the efficacy and safety of its investigational oral treatment ABX464 for ulcerative colitis (UC). One year of treatment ... Read more

October 14, 2019October 14, 2019

Prometheus and Takeda Collaborate on Development of Targeted IBD Therapies

News

Biopharmaceutical company Prometheus Biosciences is collaborating with pharmaceutical firm Takeda to discover, develop, and commercialize a new generation of targeted therapies for inflammatory bowel disease (IBD). The global, multi-target strategic ... Read more

October 2, 2019October 2, 2019

Entyvio Seen as Superior to Humira in Treating Active UC, Phase 3 Trial Shows

News

One year of treatment with Entyvio (vedolizumab) was found to be superior to Humira (adalimumab) in achieving disease remission in people with ulcerative colitis (UC), a common form of inflammatory bowel disease (IBD), Takeda ... Read more

August 26, 2019August 26, 2019

Safety Concerns Prompt Prescription Changes Among Gastroenterologists

News

A survey of gastroenterologists in the United States shows that data from the VARSITY clinical trial, as well as safety concerns about the experimental treatment Xeljanz, are affecting how some ... Read more

July 19, 2019July 19, 2019

Gene Expression Grouping Can Predict Treatment Response in Ulcerative Colitis, Study Suggests

News

People with ulcerative colitis can be divided into groups based on gene expression, and this division can help identify those more likely to respond to treatments, a recent study found. ... Read more